The Monopoly Wasn't Broken. It Was Tested.

A surgeon doesn't choose a robot because of a press release.

They choose it because it fits into a room, a team, a rhythm that took years to build.

That distinction got lost in the noise.

When Johnson & Johnson's Ottava won FDA clearance, headlines called it the end of Intuitive Surgical's two-decade monopoly in soft-tissue robotics. Intuitive's stock dropped.

Then Oppenheimer upgraded Intuitive to Outperform, and told a different story. Its field checks found unique workflow challenges for Ottava: its arms deploy into a non-sterile field after the patient is already on the table, requiring re-sterilization if there's fluid leakage. Medtronic's Hugo, meanwhile, was found to take up more real estate in the operating room than da Vinci.

This is the part the headlines missed.

Clearance is a starting line, not a finish line.

A robot can be cleared, funded, and announced, and still fail the test that matters most: does it disappear into the surgeon's hands, or does it introduce friction the team has to work around.

That test is where autonomy actually gets decided.

Every rung on the path toward autonomous surgery depends on trust built through repetition. A system a surgical team fights with every case never accumulates the volume of clean, consistent data that autonomy requires. A system that fits does.

So the real competition isn't which company got cleared first.

It's which company builds a system surgeons stop noticing.

The winner of that fight won't just take market share.

They'll take the fastest path toward the next rung of the Autonomy Ladder, because trust and data compound in the same direction.

Watch workflow, not headlines.

That's where the next era of surgical autonomy is actually being written.